Caldesmon (C-Term) Rabbit Monoclonal Antibody (RM396)

Caldesmon is an actin-binding protein that regulates actin cytoskeleton organization and assembly in smooth muscle and non-muscle cells.^1,2 It is composed of an N-terminal myosin-binding domain, a central spacer region, and a C-terminal domain that contains binding sites for actin, as well as calmodulin and tropomyosin, and is subject to phosphorylation by a variety of kinases.¹ Alternative splicing of the CALD1 pre-mRNA produces a heavy isoform, h-CaD, which is expressed by differentiated smooth muscle cells and localizes to actomyosin contractile structures, and a light isoform, l-CaD, which lacks the central spacer region and is expressed in non-muscle cells, where it localizes to podosomes and membrane ruffles.^1,2 Caldesmon regulates the interaction between actin and myosin, influencing cell contractility and cytoskeletal remodeling in an isoform- and cell-dependent manner.² It inhibits the activity of actomyosin ATPase, an effect that is enhanced by tropomyosin and reversed by Ca²⁺-calmodulin or phosphorylation. Increased caldesmon protein expression has been found in patients with metastatic oral squamous cell carcinoma (OSCC) and is associated with poor prognosis.³ Cayman's Caldesmon (C-Term) Rabbit Monoclonal Antibody (RM396) can be used for immunohistochemistry (IHC) and Western blot (WB) applications.

WARNING This product is not for human or veterinary use.

1. Wang, C.L.A. Caldesmon and the regulation of cytoskeletal functions. Adv. Exp. Med. Biol. 644, 250-272 (2008).

2. Lin, J.J.-C., Li, Y., Eppinga, R.D., et al. Roles of caldesmon in cell motility and actin cytoskeleton remodeling. International Review of Cell and Molecular Biology 274, 1-51 (2009).

3. Sekar, B., Saranyan, R., Nirmal, R.M., et al. Caldesmon expression in metastatic and non-metastatic oral squamous cell carcinoma—A mediator of epithelial mesenchymal transition. J. Orofac. Sci. 11(2), 105-109 (2019).